Haemoctin (Human Coagulation Factor Viii)

Haemoctin is indicated for several clinical situations where factor VIII replacement is required.

• Treatment of acute bleeding episodes in patients with hemophilia A.
• Routine prophylaxis to prevent spontaneous bleeds in severe hemophilia A.
• Surgical prophylaxis for patients undergoing invasive procedures.
• Management of acquired factor VIII deficiency associated with inhibitors or autoimmune conditions.
• Use in combination with other hemostatic agents as directed by a hematologist.
• Perioperative management to maintain adequate factor levels during and after surgery.

Adverse reactions to Haemoctin may vary in frequency and severity.

Common

• Headache.
• Fever or chills.
• Nausea.
• Injection site reactions such as erythema or swelling.
• Transient increase in blood pressure.

Serious

• Development of inhibitors (antibodies) against factor VIII.
• Anaphylactic or severe allergic reactions.
• Thromboembolic events including deep vein thrombosis.
• Hemolysis or renal impairment.
• Severe hypotension.

Healthcare providers should consider several precautions before prescribing Haemoctin to ensure safe use.

• Assess for a history of inhibitors to factor VIII.
• Evaluate for hypersensitivity to any component of the product.
• Monitor for signs of thrombosis, especially in patients with risk factors.
• Use caution in patients with cardiovascular disease or hypertension.
• Adjust dosage in renal or hepatic impairment as clinically indicated.
• Avoid use in patients with known severe allergic reactions to plasma-derived products.

Haemoctin may interact with other medications that affect coagulation or immune response.

Avoid

• Concurrent use of other factor VIII concentrates without medical supervision.
• Administration of antifibrinolytic agents at high doses without monitoring.

Use with caution

• Immunosuppressive therapies that may alter inhibitor development.
• Concomitant anticoagulants such as warfarin or direct oral anticoagulants, requiring close monitoring of coagulation parameters.
• Vaccines, particularly live attenuated vaccines, may require timing adjustments.
• Other hemostatic agents, including recombinant activated factor VII, should be coordinated by a specialist.